All In MedTech

Device Trial Radar · NCT04124406

Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150,000

Planned (sponsor's estimate)

Start

Oct 18, 2019

Primary completion

Dec 31, 2023

Study completion Dec 2025

Sponsor

Lead sponsor
Exact Sciences CorporationNot on our public-company list
Sponsor type
Industry
Collaborators
Mayo Clinic
First posted
Oct 11, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.

Conditions

  • Colon Cancer

Interventions

  • CologuardDevice

    multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Enrollment of SubjectsTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.